Comparative Pharmacology
Head-to-head clinical analysis: LORATADINE versus POLARAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORATADINE versus POLARAMINE.
LORATADINE vs POLARAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonist activity. It inhibits histamine-induced vasodilation and bronchoconstriction.
Competitive antagonist of histamine H1 receptors, blocking the effects of histamine in the respiratory tract, vasculature, and gastrointestinal tract.
10 mg orally once daily
4-8 mg orally every 6-8 hours; maximum 24 mg/day.
None Documented
None Documented
Loratadine: 8-14 hours (mean ~10 hours). Active metabolite descarboethoxyloratadine: 17-24 hours (mean ~20 hours). Clinically, duration supports once-daily dosing.
Clinical Note
moderateLoratadine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Loratadine is combined with Fluticasone propionate."
Clinical Note
moderateLoratadine + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Sulfisoxazole
Terminal elimination half-life: 20-25 hours (range 14-36 hours). Clinical context: Supports once-daily dosing for chronic allergic symptoms; accumulation possible with hepatic impairment.
Approximately 40% excreted in urine as metabolites (primarily descarboethoxyloratadine) and 40% in feces as metabolites; <1% excreted unchanged.
Primarily renal (40-60% as unchanged drug and metabolites), with minor biliary/fecal elimination
Category A/B
Category C
Antihistamine
Antihistamine
"The metabolism of Sulfisoxazole can be decreased when combined with Loratadine."